Agilent secures expanded CE Mark for cancer assay

LabPulse.com staff writers
Aug 22, 2021
2020 04 14 17 10 6379 Test Tubes Rd Lab 400

Agilent Technologies has received an expanded CE Mark that will allow its PD-L1 IHC 22C3 pharmDx assay -- a companion diagnostic for the Keytruda chemotherapy agent -- to be used for esophageal cancer.

The test may now be used to identify esophageal cancer patients eligible for treatment with Keytruda, a monoclonal antibody developed by Merck that boosts the body's ability to fight cancer cells.

Latest in Esophageal Cancer
Cancer Cell Microenvironment Social
At USCAP 2023, ProPhase Labs to present data about esophageal cancer screening test
March 13, 2023
Visit our Molecular Diagnostics Community
Sponsored
Visit our Molecular Diagnostics Community
April 5, 2024
Quality Check Mark Social
Lucid Diagnostics study demonstrates esophageal cell sampling in office setting
December 1, 2022
2021 04 27 15 25 5437 Pathology Digital Workstation Microscope 400
CDx Diagnostics, Avalon ink in-network lab agreement
June 13, 2022
Related Stories
Lab Diagnostic Analyzer Woman Resized
Sequencing
Agilent opens Massachusetts Customer Experience Center to showcase genomics, diagnostics solutions
2020 04 16 18 56 8041 Virus Coronavirus Sars Co V 2 400
Spectroscopy
Agilent touts study of FTIR-based saliva COVID test
2019 05 10 17 42 3167 Lab Doctors Dna 400
Chromatography
Agilent acquires Virtual Control's lab AI technology
Visit our Molecular Diagnostics Community
Sponsor Content
Visit our Molecular Diagnostics Community
More in Esophageal Cancer
At USCAP 2023, ProPhase Labs to present data about esophageal cancer screening test
By LabPulse.com staff writers
The upcoming presentation in New Orleans is scheduled for March 14 and entitled "Targeted Mass Spectrometry of Barrett's Esophagus Reveals High-Fidelity Combinatorial Molecular Correlates."
March 13, 2023
Cancer Cell Microenvironment Social
Study evaluates Prophase Labs test for esophageal cancer
By LabPulse.com staff writers
The study authors note that early detection, especially through noninvasive biomarker-based tests such as Prophase Labs' BE-Smart test, is critical to improving outcomes for esophageal cancer.
February 16, 2023
Dna Cancer Cell Social
Lucid Diagnostics study demonstrates esophageal cell sampling in office setting
By LabPulse.com staff writers
More than 90% of samples collected yielded DNA to perform molecular biomarker testing using the company’s EsoGuard Esophageal DNA test.
December 1, 2022
Quality Check Mark Social
CDx Diagnostics, Avalon ink in-network lab agreement
By LabPulse.com staff writers
The agreement makes CDx's diagnostic platform, WATS3D, available to the 565,000 members of BCBS of South Carolina, including all of its commercial and Medicare Advantage plans.
June 13, 2022
2021 04 27 15 25 5437 Pathology Digital Workstation Microscope 400
Lucid’s LucidDx Labs signs deal with MediNcrease
By LabPulse.com staff writers
This is Lucid's first agreement with a commercial payer. The deal will provide in-network access and payment for Lucid's EsoGuard DNA test to those insured by MediNcrease. The health insurance plan currently provides coverage to 8 million people.
May 8, 2022
2020 03 16 19 06 1700 Insurance Coverage 400
Lucid promotes new guideline from ACG on esophageal cancer
By LabPulse.com staff writers
The new guidelines include a reference to screening for esophageal cancer using Lucid's EsoGuard DNA test on samples collected with its EsoCheck Cell Collection device, it said.
April 3, 2022
2019 04 05 16 58 5171 Cancer Cell 400
Castle's esophagus test nabs ADLT status
By LabPulse.com staff writers
The test aims to predict whether patients with Barrett's esophagus will develop esophageal cancer or high-grade dysplasia. The status was effective March 24.
March 29, 2022
2019 05 02 23 38 2538 Check Mark 400
Lucid launches 3 new test centers
By LabPulse.com staff writers
The test centers are staffed with Lucid-employed nurse practitioners who use Lucid's EsoCheck cell collection device to collect surface esophageal cells. Then, the cells undergo Lucid's EsoGuard DNA esophageal test.
March 22, 2022
2022 03 23 21 50 7128 Stomach And Medical Icon2 400
Castle Biosciences completes Cernostics acquistion
By LabPulse.com staff writers
The acquisition expands Castle's offerings to include Cernostics' TissueCypher Barrett's Esophagus Assay, a test that predicts future development of high-grade dysplasia and/or esophageal cancer in patients with Barrett's esophagus, it said.
December 5, 2021
2020 07 02 23 31 0378 Handshake Meeting 400
Page 1 of 1